John Maslowski

John Maslowski is Chief Scientific Advisor at Castle Creek Biosciences, Inc. Previously, he served as President and Chief Executive Officer of Fibrocell Science, Inc., leading the company through a commercialization agreement and eventual acquisition by Castle Creek Holdings, Inc. in 2019. He also served as a member of Fibrocell’s Board of Directors.

Formerly, Mr. Maslowski was Fibrocell’s Senior Vice President, Scientific Affairs and Vice President, Operations, driving the U.S. FDA approval of LAVIV® (azficel-T), an autologous fibroblast cell therapy for improving the appearance of nasolabial folds in adults. Prior to Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals (now Pfizer), Merck & Co., and Teva Pharmaceutical Industries. He earned a B.S. in biology from Ursinus College and an M.S. in microbiology from Villanova University.

Mr. Maslowski currently serves on the Board of Directors of the Alliance for Regenerative Medicine and is Chairman of the Board of Falcon Therapeutics, a private Durham, N.C. company focused on the development of cell therapy products for oncology.